Molecular Partners AG
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Molecular Partners AG stands as a clinical-stage biopharmaceutical company, dedicated to the discovery, intricate design, and strategic commercialization of protein therapeutics. The firm pioneers the development of DARPin (Designed Ankyrin Repeat Protein) candidates, a distinctive class of custom-built small proteins engineered to exhibit high specificity, stability, and versatility, addressing medical challenges beyond the scope of traditional antibodies. The company's advanced pipeline primarily concentrates on oncology, featuring several innovative programs. MP0533, a multispecific T-cell engager, is progressing through Phase 1/2a clinical trials for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), demonstrating promising antitumor activity and response rates. Furthermore, Molecular Partners is advancing its Radio-DARPin Therapy (RDT) platform in collaboration with Orano Med, focusing on targeted alpha therapeutics. This includes MP0712, a DLL3-targeting Radio-DARPin, for which an IND has been filed, with Phase 1 clinical trials anticipated to commence by the end of 2025 for small-cell lung carcinoma and neuroendocrine tumors. Another RDT candidate, MP0726, targets mesothelin for ovarian cancer. The Switch-DARPin platform represents a next-generation approach to immune cell engagers, designed for conditional activation within the tumor microenvironment, with preclinical data for a CD3 Switch-DARPin T cell engager being presented. Earlier efforts leveraged DARPin technology in ophthalmology, exemplified by Abicipar for neovascular wet age-related macular degeneration and diabetic macular edema, developed through a partnership with Allergan. In virology, ensovibep (MP0420) was a multi-specific DARPin candidate for the SARS-CoV-2 virus, which achieved positive Phase 2 results and clinical validation for DARPins in infectious diseases, although Novartis later returned its rights. Molecular Partners AG was established in 2004 and is headquartered in Schlieren, Switzerland. The company's strategy involves both proprietary pipeline development and strategic collaborations, having previously engaged with leading pharmaceutical companies like Novartis, Amgen, and Allergan, and currently expanding its alliance with Orano Med.
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes
Molecular Partners to Hold Three Poster Presentations at AACR 2026
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference